Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2016 07; 142(1):25-29.
View in:
PubMed
subject areas
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carboplatin
Chemotherapy, Adjuvant
Chemotherapy, Adjuvant
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Administration Schedule
Female
Female
Humans
Humans
Middle Aged
Middle Aged
Neoadjuvant Therapy
Neoadjuvant Therapy
Neoplasm Staging
Neoplasm Staging
Neoplasms, Glandular and Epithelial
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Ovarian Neoplasms
Paclitaxel
Paclitaxel
Retrospective Studies
Retrospective Studies
Taxoids
Taxoids
Treatment Outcome
Treatment Outcome
authors with profiles
David Andrew Becker